Oncopeptides (publ)
Pharmaceutical Manufacturing • 
Stockholm, Stockholm County, Sweden • 51-100 Employees
Company overview
| Headquarters | Luntmakargatan 46, Stockholm, 11137, SE |
| Phone number | +465565966438 |
| Websites | |
| NAICS | 3254 |
| SIC | 283 |
| Keywords | Oncology, Orphan Drug, Phase 1, EMD, Multiple Myeloma, Alkylation, Anti-Angiogenic, Cytotoxicity, Efficacy Studies, Peptidase Targeting, Plasma Cell Myeloma, Relapsed & Relapsed-Refractory Multiple Myeloma, Phase 2, Rrmm, Melflufen, Peptide Conjugated Alkylator, Peptide-Drug Conjugate, Phase 3, Melphalan Flufenamide |
| Founded | 2000 |
| Employees | 51-100 |
| Socials |
Key Contacts at Oncopeptides (publ)
Giovanni Battista Gidaro
Commercial Director Italy
Sofia Heigis
Chief Executive Officer
Denise Luxenburg Stuifbergen
Business Development Project Director
David Augustsson
Director Of Corporate Affairs
Astrid Rydheim
Product Project Director
Cristina González-Junco
Medical Affairs Lead - Director Medico
Lotta Svensson
Group Accounting Director
Heiko Singer
Medical Affairs Director Dach
Lina Rörby Franzén
Global Marketing & Business Excellence Director, Country Manager Nordics/Netherlands/Ireland
Aysel Müezzinler
Associate Director, Business Operations & Analytics
Oncopeptides (publ) Email Formats
Oncopeptides (publ) uses 3 email formats. The most common is {first name}.{last name} (e.g., john.doe@oncopeptides.com), used 67.3% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@oncopeptides.com | 67.3% |
{first initial}.{last name} | j.doe@oncopeptides.com | 32.7% |
About Oncopeptides (publ)
Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug, Pepaxti, is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere. Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE. The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO. For more information, visit: www.oncopeptides.com
Oncopeptides (publ) revenue & valuation
| Annual revenue | $3,721,719 |
| Revenue per employee | $45,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $12,000,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Oncopeptides (publ) has 33 employees across 10 departments.
Departments
Number of employees
Funding Data
Oncopeptides (publ) has never raised funding before.
Oncopeptides (publ) Tech Stack
Discover the technologies and tools that power Oncopeptides (publ)'s digital infrastructure, from frameworks to analytics platforms.
Video players
Cookie compliance
Miscellaneous
JavaScript libraries
Maps
JavaScript libraries
CDN
JavaScript libraries
Webmail
Miscellaneous
Programming languages
United States
South Africa
Netherlands
Bangladesh
United KingdomFrequently asked questions
4.8
40,000 users
